CMS Updates 2005 Part B Payment Rates; Gemzar ASP Increases By 7.3%
Executive Summary
Lilly has reversed a 7% price cut for the oncologic Gemzar ahead of the 2005 transition to average sales price-based reimbursement under Medicare Part B
You may also be interested in...
Energy & Commerce Health Chairman Deal Brings Medicaid Background
Rep. Nathan Deal (R-Ga.) brings Medicaid expertise to his new role as House Energy & Commerce Health Subcommittee chairman
Energy & Commerce Health Chairman Deal Brings Medicaid Background
Rep. Nathan Deal (R-Ga.) brings Medicaid expertise to his new role as House Energy & Commerce Health Subcommittee chairman
Part B Average Sales Price Drug Rates Finalized; Zoladex Down 12%
AstraZeneca's prostate cancer therapy Zoladex will be reimbursed at 12% below CMS' previously estimated rate when payment changes for Medicare Part B-covered drugs take effect Jan. 1